247 related articles for article (PubMed ID: 19584236)
1. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells.
Bhatia V; Saini MK; Shen X; Bi LX; Qiu S; Weigel NL; Falzon M
Mol Cancer Ther; 2009 Jul; 8(7):1787-98. PubMed ID: 19584236
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE.
Sepulveda VA; Weigel NL; Falzon M
Steroids; 2006 Feb; 71(2):102-15. PubMed ID: 16243370
[TBL] [Abstract][Full Text] [Related]
3. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice.
Blutt SE; Polek TC; Stewart LV; Kattan MW; Weigel NL
Cancer Res; 2000 Feb; 60(4):779-82. PubMed ID: 10706079
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
Lokeshwar BL; Schwartz GG; Selzer MG; Burnstein KL; Zhuang SH; Block NL; Binderup L
Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
[TBL] [Abstract][Full Text] [Related]
5. Nuclear localization of parathyroid hormone-related peptide confers resistance to anoikis in prostate cancer cells.
Park SI; McCauley LK
Endocr Relat Cancer; 2012 Jun; 19(3):243-54. PubMed ID: 22291434
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer cell type-specific regulation of the human PTHrP gene via a negative VDRE.
Tovar Sepulveda VA; Falzon M
Mol Cell Endocrinol; 2003 Jun; 204(1-2):51-64. PubMed ID: 12850281
[TBL] [Abstract][Full Text] [Related]
7. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer.
El Abdaimi K; Papavasiliou V; Rabbani SA; Rhim JS; Goltzman D; Kremer R
Cancer Res; 1999 Jul; 59(14):3325-8. PubMed ID: 10416587
[TBL] [Abstract][Full Text] [Related]
8. Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein.
Blomme EA; Dougherty KM; Pienta KJ; Capen CC; Rosol TJ; McCauley LK
Prostate; 1999 May; 39(3):187-97. PubMed ID: 10334108
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling.
Bhatia V; Mula RV; Weigel NL; Falzon M
Mol Cancer Res; 2009 Jul; 7(7):1119-31. PubMed ID: 19584267
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone-related peptide: expression in prostate cancer bone metastases.
Bryden AA; Islam S; Freemont AJ; Shanks JH; George NJ; Clarke NW
Prostate Cancer Prostatic Dis; 2002; 5(1):59-62. PubMed ID: 15195132
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer.
Oades GM; Dredge K; Kirby RS; Colston KW
BJU Int; 2002 Oct; 90(6):607-16. PubMed ID: 12230626
[TBL] [Abstract][Full Text] [Related]
12. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
Haq M; Kremer R; Goltzman D; Rabbani SA
J Clin Invest; 1993 Jun; 91(6):2416-22. PubMed ID: 8514854
[TBL] [Abstract][Full Text] [Related]
13. Direct evidence that PTHrP expression promotes prostate cancer progression in bone.
Deftos LJ; Barken I; Burton DW; Hoffman RM; Geller J
Biochem Biophys Res Commun; 2005 Feb; 327(2):468-72. PubMed ID: 15629138
[TBL] [Abstract][Full Text] [Related]
14. The noncalcemic vitamin D analogues EB1089 and 22-oxacalcitriol interact with the vitamin D receptor and suppress parathyroid hormone-related peptide gene expression.
Falzon M
Mol Cell Endocrinol; 1997 Mar; 127(1):99-108. PubMed ID: 9099905
[TBL] [Abstract][Full Text] [Related]
15. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo.
Rabbani SA; Gladu J; Harakidas P; Jamison B; Goltzman D
Int J Cancer; 1999 Jan; 80(2):257-64. PubMed ID: 9935208
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP.
Burton DW; Geller J; Yang M; Jiang P; Barken I; Hastings RH; Hoffman RM; Deftos LJ
Prostate; 2005 Feb; 62(3):275-81. PubMed ID: 15389781
[TBL] [Abstract][Full Text] [Related]
17. Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein.
Yan Z; Jin S; Wei Z; Huilian H; Zhanhai Y; Yue T; Juan L; Jing L; Libo Y; Xu L
Biochim Biophys Acta; 2014 Sep; 1842(9):1350-63. PubMed ID: 24787381
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma.
Dougherty KM; Blomme EA; Koh AJ; Henderson JE; Pienta KJ; Rosol TJ; McCauley LK
Cancer Res; 1999 Dec; 59(23):6015-22. PubMed ID: 10606251
[TBL] [Abstract][Full Text] [Related]
19. Effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and its analogues (EB1089 and analog V) on canine adenocarcinoma (CAC-8) in nude mice.
Kunakornsawat S; Rosol TJ; Capen CC; Reddy GS; Binderup L; Inpanbutr N
Biol Pharm Bull; 2002 May; 25(5):642-7. PubMed ID: 12033506
[TBL] [Abstract][Full Text] [Related]
20. PTHrP contributes to the anti-proliferative and integrin alpha6beta4-regulating effects of 1,25-dihydroxyvitamin D(3).
Shen X; Mula RV; Li J; Weigel NL; Falzon M
Steroids; 2007 Dec; 72(14):930-8. PubMed ID: 17904173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
